← Leaderboards
David Woosuk Chang
Fibralign Corporation
$484,031
Attributed
$968,062
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $682.3K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$968,062 · 1
By mechanism
R44$968,062 · 1
Top collaborators
- Michael Vitoldovich Paukshto3 shared
Most similar at Fibralign Corporation
Same institution · by research overlap
- Michael Vitoldovich Paukshto$2,031,437
- Michael Paukshto$179,964
Others in their field
Other Emerging Leaders on “Advanced Development”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Kimberly Smith · Ppd Development Lp$115,671,664
Research focus
Advanced DevelopmentAftercareAnimalsAffectAutologousBaseBlindedBreast Cancer SurvivorBreast Cancer SurvivorshipAnticancer ResearchCell-Matrix JunctionChronicChronic DiseaseClinical InvestigationClinical ResearchCohortCollagenCommercializationComprehensionCutaneousDeformityDepositionDermalDesign
Grant awards (3)
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$682,266
R44 · FY2021 · CA
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$32,935
R44 · FY2020 · CA
Prospective evaluation of a surgical solution for breast cancer-associated lymphedema$252,861
R44 · FY2019 · CA